CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS

HIV

Having the Courage of Our Convictions

1-2 October 2015
City Hall, 4th Arrondissement, Paris
Dear Colleagues:

On behalf of the International Association of Providers of AIDS Care (IAPAC), I welcome you to our fourth Controlling the HIV Epidemic with Antiretrovirals summit, which we are proud to sponsor in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the City of Paris, the 4th Arrondissement of the City of Paris, and the AIDS Healthcare Foundation (AHF).

In designing this year's summit program, the Co-Chairs and I chose the summit's motto, “Having the Courage of Our Convictions,” in acknowledgement of the global consensus around the goal of ending AIDS as a public health threat by 2030, but concerned about the pace at which progress is being made. Moreover, guiding the planning committee's selection of this year's summit themes were the following sobering statistics:

- **4,600** babies are born HIV infected weekly
- **36,500** adults become HIV infected weekly, of whom 7,000 are young women
- **3,600** children and **25,000** adults die weekly of AIDS-related complications

In addition to delving into questions regarding leadership, resources, and the commitment necessary to attain new global targets – 90-90-90 – by 2020 and, ultimately, to achieve HIV control by 2030, we aim to move from restating our consensus to discussing concrete actions (e.g., large-scale interventions) that will allow us to demonstrate results within the five-year (2020) and 10-year (2030) time horizons we have set for our goal and targets. But these discussions cannot end here. I believe that the faculty we have assembled, and the delegates who are joining us from 25 countries, represent a critical mass of clinicians, researchers, policy makers, donors, and people living with HIV that needs to engage in the type of activism necessary to shape our response at this critical juncture in the global HIV epidemic.

My sincere gratitude to Paris Mayor Anne Hidalgo and to the 4th Arrondissement’s Mayor, Christophe Girard, for their hospitality and warm welcome to the City of Lights, as well as their continued leadership in the fight against HIV/AIDS. I am grateful to UNAIDS and AHF, to our generous sponsors, to our distinguished faculty, and to each and every delegate who traveled from near and far to be a part of this fourth IAPAC summit.

I wish you a successful two days of collegial and productive deliberations.

José M. Zuniga, PhD, MPH
President, IAPAC
Dear Colleagues:

Welcome to the fourth annual Controlling the HIV Epidemic with Antiretrovirals summit, organized by the International Association of Providers of AIDS Care (IAPAC). We are here these two days to explore the ways in which we will improve population health in heavily HIV affected regions within the next five years, setting the stage for ending AIDS as a public health threat by 2030.

The rationale for this annual summit is more compelling than ever, given the culmination of several important studies this past year. The START study convincingly demonstrated that the initiation of antiretroviral (ART) as soon as patients are diagnosed with HIV and understanding the importance of daily adherence results in decreased HIV morbidity and mortality. Moreover, the data from START and TEMPRANO offer hope that early ART initiation can significantly decrease the global TB syndemic.

Additionally, with the final report from the HPTN 052, we now definitively know that early ART initiation is among the most effective HIV prevention interventions, reducing transmission by more than 90% after close to 10,000 person years of follow-up. The beneficial findings associated with early ART are also complemented by additional reports that the use of pre-exposure prophylaxis (PrEP) can effectively decrease HIV acquisition among high-risk populations. A pragmatic study, PROUD, conducted in British genitourinary medicine clinics, demonstrated that the integration of PrEP within the context of sexual health primary care provision can be highly effective, approaching 90% protection in a very real-world setting.

The challenge for our discussions this year in Paris is to how to best translate these exciting research findings into public health policy. We have the tools to turn the tide on this persistent global pandemic. The question is whether we have the courage of our convictions, the political will, and the organization to successfully implement these findings into clinical practice.

We hope that the scheduled plenaries and panels as well as formal and informal discussions throughout the next two days will provide you with new information, new insights, and new contacts to facilitate further optimization of the use of antiretrovirals to control the HIV epidemic and, ultimately, to end AIDS as a public health threat by 2030.

Best wishes for a productive summit,

Kenneth H. Mayer, MD
Fenway Institute
Boston, MA, USA

Julio S.G. Montaner, MD
BC Centre for Excellence in HIV/AIDS
Vancouver, BC, CANADA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900-0915</td>
<td>Welcome from IAPAC and the Summit Co-Chairs</td>
</tr>
<tr>
<td>0915-0930</td>
<td>Welcome from the City of Paris</td>
</tr>
<tr>
<td>0930-1030</td>
<td>Leadership to End AIDS as a Public Health Threat by 2030 – Do We Have What it Takes?</td>
</tr>
<tr>
<td>1030-1100</td>
<td>Joep MA Lange, MD, PhD, Memorial Lecture</td>
</tr>
<tr>
<td>1100-1130</td>
<td>BREAK</td>
</tr>
<tr>
<td>1130-1200</td>
<td>What Do Advances in HIV Treatment Mean in the Context of Ending AIDS?</td>
</tr>
<tr>
<td>1200-1245</td>
<td>Community-Based TasP Trials: Updates and Projected Contributions</td>
</tr>
<tr>
<td>1345-1430</td>
<td>TasP Implementation: Strategic Lessons from the Frontlines</td>
</tr>
<tr>
<td>1515-1600</td>
<td>Early PrEP Implementation: Perspectives from the Field</td>
</tr>
<tr>
<td>1600-1630</td>
<td>Putting It All Together: TasP, PrEP, and an Evolving HIV Prevention Paradigm</td>
</tr>
<tr>
<td>1630-1700</td>
<td>BREAK</td>
</tr>
<tr>
<td>1700-1800</td>
<td>Situation Report: A Reality Check on Our Quest to End AIDS by 2030</td>
</tr>
<tr>
<td>1800</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>
Controlling the HIV Epidemic with Antiretrovirals – 1-2 October 2015

FRIDAY 2 OCTOBER 2015

PROGRAM AT-A-GLANCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900-0930</td>
<td><strong>90-90-90 and PEPFAR 3.0: Pivoting Toward HIV Control</strong>&lt;br&gt;<strong>Douglas N. Shaffer, MD, MHS</strong></td>
</tr>
<tr>
<td>0930-1000</td>
<td><strong>Where is the Demand? – Clearing Bottlenecks to Attaining the 90-90-90</strong>&lt;br&gt;<strong>Targets</strong>&lt;br&gt;<strong>Reuben Granich, MD, MPH</strong></td>
</tr>
<tr>
<td>1000-1045</td>
<td><strong>WHO Early Release Guidance on ART Initiation and PreP; and IAPAC Guidelines on Optimizing the HIV Care Continuum to Attain the 90-90-90 Targets</strong>&lt;br&gt;<strong>Meg Doherty, MD, MPH, PhD</strong>&lt;br&gt;<strong>Julio S.G. Montaner, MD</strong></td>
</tr>
<tr>
<td>1045-1115</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>1115-1200</td>
<td><strong>What Will It Take to Optimize TasP, Attain 90-90-90, and Control HIV?</strong>&lt;br&gt;<strong>Moderator:</strong> Christine Katlama, MD&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;<strong>K. Rivet Amico, PhD</strong>&lt;br&gt;<strong>Julio S.G. Montaner, MD</strong>&lt;br&gt;<strong>Terri Ford</strong>&lt;br&gt;<strong>Badara Samb, MD, PhD</strong></td>
</tr>
<tr>
<td>1200-1245</td>
<td><strong>Ending AIDS: Way Outside the Box Thinking…</strong>&lt;br&gt;<strong>Moderator:</strong> Kenneth Mayer, MD&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;<strong>Michael Ruffner, MPP</strong>&lt;br&gt;<strong>Katie Callahan, MPH</strong></td>
</tr>
<tr>
<td>1245-1345</td>
<td><strong>LUNCH</strong></td>
</tr>
<tr>
<td>1345-1440</td>
<td><strong>Meeting Demand: Industry Innovations to Achieve the 90-90-90 Targets</strong>&lt;br&gt;<strong>Moderator:</strong> José M. Zuniga, PhD, MPH&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;<strong>Gavin Cloherty, PhD</strong>&lt;br&gt;<strong>James Rooney, MD</strong>&lt;br&gt;<strong>Sandra Lehrman, MD</strong>&lt;br&gt;<strong>Alex Rinehart, PhD</strong></td>
</tr>
<tr>
<td>1440-1535</td>
<td><strong>Fast-Track Cities: Focusing on Urban HIV Epidemics to Attain 90-90-90</strong>&lt;br&gt;<strong>Moderators:</strong>&lt;br&gt;<strong>Bertrand Audoin, MBA</strong>&lt;br&gt;<strong>Michael Hahn, MD</strong>&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;<strong>Serge Eholié, MD, PhD</strong>&lt;br&gt;<strong>France Lert, PhD</strong>&lt;br&gt;<strong>Praphan Phanuphak, MD, PhD</strong></td>
</tr>
<tr>
<td>1535-1600</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>1600-1700</td>
<td><strong>Closing the Gaps: What Does It Mean to Leave No One Behind?</strong>&lt;br&gt;<strong>Moderator:</strong> Gas Cairns, MA&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;<strong>Gregorio Millett, MPH</strong>&lt;br&gt;<strong>Kate Shannon, PhD</strong>&lt;br&gt;<strong>Imane Sidibé, MSc</strong>&lt;br&gt;<strong>Anna Zakowicz, MPH, MA</strong></td>
</tr>
<tr>
<td>1700-1715</td>
<td><strong>Having the Courage of our Convictions</strong></td>
</tr>
<tr>
<td>1715-1730</td>
<td><strong>Acting in Solidarity: Overcoming Political/Programmatic Challenges to Fast-Track the 90-90-90 Targets</strong>&lt;br&gt;<strong>Luiz Loures, MD</strong></td>
</tr>
<tr>
<td>1730</td>
<td><strong>ADJOURN</strong></td>
</tr>
</tbody>
</table>
K. Rivet Amico, PhD
University of Michigan
Ann Arbor, MI, USA

Jane Anderson, MBBS, PhD
Public Health England
London, ENGLAND

Bertrand Audoin, MBA
International Association of Providers of AIDS Care
Geneva, SWITZERLAND

Paul Benkimoun, MD
Le Monde
Paris, FRANCE

David Burns, PhD
National Institute of Allergy and Infectious Diseases
Bethesda, MD, USA

Gus Cairns, MA
European AIDS Treatment Group
London, ENGLAND

Katie Callahan, MPH
Clinton Health Access Initiative
Boston, MA, USA

Gavin Cloherty, PhD
Abbott Molecular
North Chicago, IL, USA

Dominique Costagliola, PhD
University Pierre and Marie Curie
Paris, FRANCE

François Dabis, MD
Bordeaux Segalen University
Bordeaux, FRANCE

Nikos Dedes
Positive Voice
Athens, GREECE

Meg Doherty, MD, MPH, PhD
World Health Organization
Geneva, SWITZERLAND

Serge Eholié, MD, PhD
Félix Houphouët-Boigny Abidjan, CÔTE D’IVOIRE

Sarah J. Fidler, MBBS, PhD
Imperial College
London, ENGLAND

Terri Ford
AIDS Healthcare Foundation
Los Angeles, CA, USA

Marcel Araujo de Freitas, MD, PhD
Ministry of Health
Sao Paulo, BRAZIL

Reuben Granich, MD, MPH
International Association of Providers of AIDS Care
Washington, DC, USA

Robert M. Grant, MD, MPH
University of California
San Francisco, CA, USA

Michael Hahn, MD
Joint United Nations Programme on HIV/AIDS
Geneva, SWITZERLAND

Mark Harrington
Treatment Action Group
New York, NY, USA

Mayor Anne Hidalgo
City of Paris
Paris, FRANCE

ChristineKatlama, MD
Hospitalet Pitié-Salpêtrière
Paris, FRANCE

Sandor Lehman, MD
Merck & Co.
Philadelphia, PA, USA

France Lert, PhD
Agence Nationale de Recherche sur le Sida
Paris, FRANCE

Luiz Loures, MD
Joint United Nations Programme on HIV/AIDS
Geneva, SWITZERLAND

Lelio Marmora, JD
UNITAID
Geneva, SWITZERLAND

Kenneth Mayer, MD
Fenway Institute
Boston, MA, USA

Sheena McCormack, MSc
University College London
London, ENGLAND

Jonathan Mermin, MD
Centers for Disease Control and Prevention
Atlanta, GA, USA

Ambassador Philippe Meunier
Ministry of Foreign Affairs and International Development
Paris, FRANCE

Gregorio Millett, MPH
Foundation of AIDS Research
Washington, DC, USA

Jean-Michel Molina, MD
Hospital Saint-Louis
Paris, FRANCE

Julio S.G. Montaner, MD
BC Center of Excellence in HIV/AIDS
Vancouver, BC, CANADA

Peter Mugyenyi, MD
Joint Clinical Research Center
Kampala, UGANDA

Sabin Nsanzimana, MD
Rwanda Biomedical Center
Kigali, RWANDA

Velephi Okello, MBBS, MPH
Ministry of Health
Mbahane, SWAZILAND

Praphan Phanuphak, MD, PhD
Chulalongkorn University
Bangkok, THAILAND

Nittaya Phanuphak, MD, PhD
Thai Red Cross AIDS Research Centre
Bangkok, THAILAND

Deenan Pillay, MD
University College London
London, ENGLAND

Alex Rinehart, PhD
ViiV Healthcare
Collegeville, PA, USA

James Rooney, MD
Gilead Sciences
Foster City, CA, USA

Michael Ruffner, MPP
Office of the Global AIDS Coordinator
Washington, DC, USA

Jorge Saavedra, MD
AIDS Healthcare Foundation
Mexico City, MEXICO

Badara Samb, MD, PhD
Joint United Nations Programme on HIV/AIDS
Geneva, SWITZERLAND

Douglas N. Shaffer, MD, MHS
Office of the Global AIDS Coordinator
Washington, DC, USA

Kate Shannon, PhD
BC Centre for Excellence in HIV/AIDS
Vancouver, BC, CANADA

Imane Sidibé, MSc
International Association of Providers of AIDS Care
Washington, DC, USA

Michel Sidibé, MEcon
Joint United Nations Programme on HIV/AIDS
Geneva, SWITZERLAND

Kenly Sikwese
African Community Advisory Board
Lusaka, ZAMBIA

Francois Venter, MD
University of the Witwatersrand
Johannesburg, SOUTH AFRICA

Patrick G. Yeni, MD
Hôpital Bichat-Claude Bernard
Paris, FRANCE

Benjamin Young, MD, PhD
International Association of Providers of AIDS Care
Washington, DC, USA

Anna Zakowicz, MPH, MA
AHF Europe
Amsterdam, NETHERLANDS

José M. Zuniga, PhD, MPH
International Association of Providers of AIDS Care
Washington, DC, USA

4

Controlling the HIV Epidemic with Antiretrovirals - 1-2 October 2015
PROGRAM OVERVIEW
The International Association of Providers of AIDS Care (IAPAC), in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS), City of Paris, and AIDS Healthcare Foundation (AHF), is hosting this two-day Controlling the HIV Epidemic with Antiretrovirals summit with a goal of leveraging antiretrovirals to end AIDS as a public health threat by 2030.

The summit will feature data related to and discussion about the implementation of combination prevention, including treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). The summit will also allow clinicians, researchers, public health policy-makers, government officials, donor agency managers, civil society representatives, and other stakeholders to explore ways of generating demand for and increasing access to HIV testing, care, and treatment services globally.

DISCLOSURE
Gilead Sciences and ViiV Healthcare have provided educational grants in support of this summit. IAPAC is responsible for control of the summit’s content and faculty selection. In awarding educational grants, neither Gilead Sciences nor ViiV Healthcare had any involvement in the content of the program or the selection of presenters, panelists, and/or moderators.

MEETING VENUE
Controlling the HIV Epidemic with Antiretrovirals is being held at the City Hall of Paris’ 4th Arrondissement.

MEALS
Coffee breaks will take place as scheduled in the summit program in the Salle de Mariage (Wedding Hall). Neither lunch nor dinner will be provided on either day. Please check with summit staff in the Registration Area to coordinate a reservation at a restaurant in close proximity to the 4th Arrondissement’s City Hall.

INTERNET ACCESS
Internet access is only available in the Salle de Fête (Banquet Hall).

SLIDE PRESENTATIONS
The summit’s presentations will be posted at www.iapac.org as they are delivered.

SOCIAL MEDIA
IAPAC encourages you to use social media to communicate your thoughts about the summit proceedings. The summit’s Twitter hashtag is #tasp2015.

QUESTIONS
If you have any questions during the summit, please locate an IAPAC staff member in the Registration Area. If you have any questions post-summit, please contact Jonathan Hess, IAPAC’s Conference Manager, at jhess@iapac.org.
Controlling the HIV Epidemic with Antiretrovirals: Having the Courage of our Convictions is sponsored by the International Association of Providers of AIDS Care (IAPAC), in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS), City of Paris, and AIDS Healthcare Foundation (AHF). We wish to express our gratitude to the institutional and commercial supporters whose generosity has made our 2015 summit possible.